Suzuken Co., Ltd. (SZUKF)

USD 30.3

(0.0%)

EBITDA Summary of Suzuken Co., Ltd.

  • Suzuken Co., Ltd.'s latest annual EBITDA in 2024 was 340.78 Million USD , up 30.19% from previous year.
  • Suzuken Co., Ltd.'s latest quarterly EBITDA in 2024 FY was N/A , down -7.63% from previous quarter.
  • Suzuken Co., Ltd. reported an annual EBITDA of 297.16 Million USD in 2023, up 26.03% from previous year.
  • Suzuken Co., Ltd. reported an annual EBITDA of 267.43 Million USD in 2022, up 40.53% from previous year.
  • Suzuken Co., Ltd. reported a quarterly EBITDA of N/A for 2024 FY, down -7.63% from previous quarter.
  • Suzuken Co., Ltd. reported a quarterly EBITDA of 83.59 Million USD for 2024 Q3, down -17.87% from previous quarter.

Annual EBITDA Chart of Suzuken Co., Ltd. (2024 - 2016)

Historical Annual EBITDA of Suzuken Co., Ltd. (2024 - 2016)

Year EBITDA EBITDA Growth
2024 340.78 Million USD 30.19%
2023 297.16 Million USD 26.03%
2022 267.43 Million USD 40.53%
2021 22.78 Billion USD -56.78%
2020 52.58 Billion USD 16.3%
2019 56.3 Billion USD 17.2%
2018 39.86 Billion USD 6.09%
2017 281.85 Million USD -23.07%
2016 366.36 Million USD 0.0%

Peer EBITDA Comparison of Suzuken Co., Ltd.

Name EBITDA EBITDA Difference
China Medicine Corporation 13.27 Million USD -2466.434%
DH Enchantment Inc. -145.23 Thousand USD 234750.178%
Exlites Holdings International, Inc. -90.49 Thousand USD 376684.325%
Itonis, Inc. -38.31 Thousand USD 889639.162%
One Step Vending Corp. -26.55 Thousand USD 1283553.047%
MediPal Holdings Corporation 431.52 Million USD 21.028%
PD-Rx Pharmaceuticals, Inc. -51.41 Thousand USD 662855.894%
Pharmagen, Inc. -2.89 Million USD 11877.248%